Bishal Gyawali: Quality of Life reporting remains disappointing even for those trials that lead to drug approvals
Bishal Gyawali shared a post on X about a recent paper by Medhavi Gupta et al. published in BMJ Journals, commenting:
“Published today in BMJ Oncology. Quality of Life reporting remains disappointing even for those trials that lead to drug approvals. Physicians and patients are forced to make decisions about new drugs without knowing how it will affect their quality of life.
Kudos to Medhavi Gupta, Pallawi Torka and colleagues for the persistence in taking this past the finish line.” .
Authors: Medhavi Gupta, Othman Salim Akhtar, Bhavyaa Bahl, Angel Mier-Hicks, Kristopher Attwood, Kayla Catalfamo, Bishal Gyawali, Pallawi Torka.
Source: Bishal Gyawali/X
Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives.
Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.
